ebbu’s approach is to dial in the best formulations of a number of cannabinoids and terpenes, to take advantage of the entourage effect and produce the most effective, consistent mood sensations and experiences, as well as health benefits.
The progress of cannabis research has been hampered in the U.S. by the federal status of marijuana. As we’ve learned at our ebbu laboratory headquartered in Colorado, having access to a variety of strains is crucial to conducting research.
By ebbu Staff
ebbu’s wide-ranging mission to propel cannabis science and unlock the secrets of the plant’s fundamental compounds starts with revolutionary hemp cultivation.
Collaborations with two of Colorado’s leading hemp growers are advancing ebbu’s groundbreaking genetic research, development of specialized cannabinoid formulations that create consistent mood effects and our in-depth study of rare cannabinoids, the entourage effect and more.
Hardy Boy Farms, one of Colorado’s largest greenhouse operators, teamed up with ebbu on a new indoor cultivation / research facility, and we’ve also partnered with sustainability-minded Colorado Cultivars to pursue cannabinoid-focused plant development for outdoor cultivation.
State-certified hemp cultivator Hardy Boy Farms provided approximately 150,000 square feet of greenhouse space and built an on-site research laboratory for ebbu’s horticultural scientists. The 1,500 square-foot space gives ebbu’s botanists the opportunity to test how particular strains perform in the greenhouse environment, and to continue their patented work in plant genetics to maximize cannabinoid output and develop plants with rare-cannabinoid profiles.
Hardy Boy Farms’ growers are trained with genetics in mind, with a biologist and soil scientist on-site. The family business founded in 1948 is one of the largest cultivators in the state, with a million square feet of greenhouse space across three locations in the Denver Metro area,
ebbu is pursuing additional hemp cultivation projects with the largest hemp farming operation in Colorado: sustainability-minded Colorado Cultivars.
Colorado Cultivars’ massive hemp farm measures 2,000 acres and is registered with the Colorado Department of Agriculture. The majority of its acreage is USDA Certified Organic, with organic farming practices used on the remainder.
The ebbu-Colorado Cultivars partnership is focused on outdoor cultivation and development of plants that produce higher yields of various cannabinoids in the outdoor environment, including cannabidiol (CBD) and producing unique products with a specific genetic profile.
Colorado Cultivars, formed in 2014, produces CBD oil and several food components, including hemp hearts, powder and oil that is a key ingredient in some of Colorado’s best-known hemp products. It is well positioned to offer leading-edge hemp genetics, as it has been a forerunner in high-yield CBD genetics. The company holds a master research contract with Colorado State University to study hemp food nutrition, the medical impacts of hemp-derived cannabinoid oil and phytoremediation of contaminated soil.
In the first year of the partnership that launched in the spring of 2018, Colorado Cultivars dedicated 250 acres for growing up to 400,000 cannabinoid-rich hemp plants.
The first crop was comprised of two hemp varieties: one that produces large amounts of CBD, the other a prime source for cannabigerol (CBG), a lesser-known but powerful cannabinoid. ebbu provided inoculated plants known as “mothers” to Colorado Cultivars for production of clone plants to be planted in the field with the guidance and expertise of ebbu’s scientists. After Colorado Cultivars has harvested and processed the specialized crops in the fall of 2018, it will distribute the resulting CBD and CBG products to ebbu’s clients.
These two hemp-growing partnerships are key to helping ebbu pursue genetic development of a crop whose domestic production has surged in recent years after Congress opened the door to hemp cultivation with the 2014 Farm Bill.
An analysis by Marijuana Business Daily found the amount of acreage for hemp grew by 140% between 2016 and 2017 among the top 10 states that produce hemp. As of summer 2018, at least 38 states have passed laws allowing hemp farming, according to the National Conference of State Legislatures.
By ebbu Staff
Colorado’s cannabis legalization forever changed one young scientist’s career path. And in the past few years, Robert Roscow Jr. has been riding the bleeding edge of cannabis science as one of the first researchers to apply genome editing techniques to Cannabis sativa L.
But in those historic early days as the U.S. cannabis industry was taking off, Mr. Roscow wasn’t studying plants; he researched other organisms at the University of Colorado-Boulder as an Ecology and Evolutionary Biology Ph.D candidate.
He studied the developmental biology of vertebrates, how multicellular organisms use their DNA, divide their cells, and make structures like arms, heads and tails. He was comparing and contrasting how different but related organisms use the same genes in different ways—like fish that create colors or patterns, for example.
As he began exploring the cannabis industry, Mr. Roscow realized that his work could have applications to cannabis plant science. “The genetic work I was doing was universal to anything that had DNA,” he says.
He became interested in joining ebbu when he met founder Jon Cooper in 2015 and heard his vision for the company.
“In about 45 seconds of hearing him talk about what he was trying to do, and seeing how it matched with what I was interested in, I was very interested in working with him.”
Mr. Cooper shared how ebbu wanted to make cannabis products similar to what you might find in a pharmacy, or the energy-drink section of a grocery store. He understood the need to create a precise cannabis formulation—and to be able to do that repeatedly.
That grabbed Mr. Roscow’s attention.
“ebbu was the only company that was bringing this technology to the table,” he says.
And that was enough to pull him away from his graduate studies and enter the cannabis industry. Mr. Roscow has found the transition from academia to Director of Genetic Research for ebbu gratifying.
“I really enjoy being able to do research in a relatively quick fashion and have that apply to help people in the real world. In academia, it is rare to see results of research go into people’s hands so quickly. If we are working on a formulation for anti-anxiety, we can hear back from people who are buying products and seeing benefits. It’s very satisfying, and what I love the most.”
At ebbu, Mr. Roscow is pursuing two main projects that are focused on cannabinoids, the building blocks of cannabis. He and his team of four full-time staff members are leveraging the diversity of the Cannabis sativa L. species to enhance resin production and increase efficiency of rare cannabinoid production.
As the results of this work have come in, Mr. Roscow has filed multiple patent applications on behalf of ebbu.
Mr. Roscow says working with the other divisions at ebbu is one of the things he enjoys most about going to work each day.
“In academia, there were lab groups, but they didn’t collaborate into the future. Within ebbu, we have a great skills overlap, so there’s more than one person thinking about a problem. We can walk down the hall to someone else’s desk or office and bounce an idea off of three other people to get their input. The science team has cross-disciplinary meetings. I love seeing the results, and what it’s going to mean for the future of cannabis research.”
Mr. Roscow looks forward to continuing work with other ebbu scientists to make effective cannabis products accessible to the general public, in a wider variety of delivery formats.
“The thing that keeps me intrigued is that what we’re working on in the cannabis industry and molecular biology are both moving forward at a fast pace,” he says. “New tools are available to us every year. Both the output of our work and the raw tools that go into the work give us an exciting environment.”
Meet Dr. Jon Martin, ebbu’s Director of Clinical Pharmacology
By ebbu Staff
Ebbu’s cannabis science lab truly takes a team to carry out our innovative research and development. Dr. Jon Martin, a molecular and cell biologist with added expertise in biochemistry, plays a key role as the company’s Director of Clinical Pharmacology.
While his title might sound intimidating, it basically means he’s in charge of measuring the effects that ebbu cannabinoid, terpene formulations have on people. He works in tandem with the cellular pharmacology team, which tests formulations on cultures of cells to see how different cannabis formulations affect specific human receptor activity.
People in the cannabis community have known for decades about the “couch-lock” body-high effects of indica strains or the energizing, cerebral stimulation tied to sativa strains, and Dr. Martin sees his work as a more rigorous, controlled way to move beyond anecdotal reports to statistically confirm effects of specific formulations of cannabinoids and terpenes.
When the cell lab reports which combinations increase receptor activity in cells the most, Dr. Martin creates a small-batch formulation to submit to human volunteers. He decides how much of each cannabinoid or terpene to put in the formula. Then he calls on a set of vetted volunteer participants to try it out and report to him what they experience.
After he collects the results from the volunteers, he can tweak the formulation and pass it back to the cell lab to do more testing, and continue that cycle until they get the formula just right.
Dr. Martin specifically appreciates the collaborative scientific effort at ebbu.
“You’re focused on your subject matter, and you’re trying to contribute good work to the other members of the science group, and it’s challenging. And everyone is with you and trying to make best use of your contribution. You can think about all the ways that it can do good. You ask questions like, ‘What would happen if we could make a topical?’ It’s fun to come up with something and make it real.”
So how did he get such a cool job? His background started with plants, but then it branched out.
Dr. Martin earned his Bachelor of Science in Plant Biotechnology from the University of California-Davis. He went on to earn his Ph.D in Plant Molecular and Cellular Biology from the University of Florida. His dissertation was on chloroplast biogenesis in plant systems, requiring research in biochemistry and molecular biology.
He conducted post-doctoral research at the University of Colorado at Boulder, working with human brain cells, looking at how neurons grow and assume shape.
In subsequent research before joining ebbu, he applied his expertise in genetics and molecular biology to modify yeast to synthesize isobutanol, an alcohol that has industrial applications including processing into renewable jet fuel.
When he was first approached by a colleague to consider working at ebbu, he was a bit wary, as he didn’t know much about cannabis. But as he dug into the science of the plant and learned about the business around it he realized, “Cannabis is a really fascinating and exciting industry.”
Dr. Martin loves the “collaborative, positive, congenial environment” at ebbu, where scientists work in several disparate, yet complementary areas, like cell biology, plant genetics, clinical research and chemistry.
“All the areas are technically sophisticated—cannabis science is challenging!”
He says focusing on any of these areas could be the work of an entire company. “But ebbu is succeeding with all of these subjects—it’s amazing.”
He says the best part of working with his colleagues is sharing their discoveries. “We’re all trying to succeed within our projects, and we’re all cheering each other on. We each benefit from eachother’s successes.”
As for his specific area of research, he admits he was initially skeptical about measuring mood effects in a group of human participants. Humans are complex, and studying their emotional states isn’t easy because it typically doesn’t conform to objective scientific models. He was worried that the effects reported by study participants would be all over the map, and it would be hard to measure and interpret data.
But it turned out that exercising some thoughtfulness around experimental design permitted measuring statistically significant effects for each formulation.
As a non-consumer himself, he likes that the research he’s doing means less guesswork for consumers. “You don’t have to be so savvy about strains. You can focus on mood effect or therapeutic effect. You can enjoy being a connoisseur if you like, but it isn’t necessary — the only thing you need to know is what you want.”
While he admits his trials are different than more formal and in depth clinical trials take years to conduct and cost tens of millions of dollars, Dr. Martin is excited about ebbu’s research into the cannabis plant’s dozens of cannabinoids. “By accessing and testing precise formulations of cannabinoids and terpenes, ebbu is breaking new ground,” he says. “There are not a lot of public results out there for the types of formulations and data that we are collecting. We think our work will be pretty impactful.”
by ebbu Staff
This morning, after a cup of coffee, a cannabis consumer sprinkled five milligrams of CBD powder on her scrambled eggs for an extra jolt of morning goodness right before a trail hike.
After his shower, an older patient stuck a small cannabis-infused transdermal patch on his arm to relieve the pain of arthritis throughout the day.
After dinner, an adult-use consumer drank some cannabis-infused sparkling water to wash down a brownie containing 10 milligrams of THC, then joined some friends out for a concert.
Cannabis consumers, welcome to a new era, where basically anything you can eat, drink or put on your skin now comes with the option of cannabis infusion.
According to Top Ten Cannabis Market Trends for 2018, a report by cannabis market research firm BDS Analytics, today’s cannabis consumers are a mix of people buying medical and recreational products. It’s these consumers, plus new consumers just entering the market in the 29 states where medical or adult-use cannabis is legal, who are creating demand for more research to develop and market new products. The BDS report suggests that new alternative delivery systems are on the horizon as industry scientists expand the knowledge base on the plant.
More and more of these consumers are first-timers, who are driving innovations in the industry. Many of them, especially medical cannabis patients, are looking for healthier options for consuming cannabis than the traditional joint or bowl.
That’s why cannabis-infused sweet or savory edibles, like brownies, gummies, crackers, popcorn and—well, you name it—have become best sellers. Products from top cannabis edible companies like Wana Brands, Keef Brands, incredibles and Dixie Brands, have quickly established the first true multistate (and soon multicountry) cannabis brands in the industry.
For those who still want the experience of inhaling their cannabis, there are plenty of alternatives to packing flower into a pipe. On shelves and readily available in most markets are cannabis concentrates: extracts that have been processed or refined to concentrate the THC potency.
These concentrates are known by an array of names like shatter, wax, oil, butter, live resin, bubble hash and clear isolates, among others. There are also concentrate cartridges filled with CO2 oil or distillates (purified oil) used in vape pens.
Researchers are working on other cannabis products intended to go directly into the bloodstream and bypass the lungs and the gut for a quicker result. The cannabinoid particles in ebbu’s water-soluble HydroPS drops for example are a miniscule 25 nanometers in diameter, and pass through soft tissue or mucosal membranes, becoming immediately bioavailable.
These include marijuana topicals, a.k.a. lotions and salves that are applied on the skin to address pain and inflammation locally; THC-infused sublinguals sprayed under the tongue; cannabis-infused tinctures applied using a dropper for absorption under the tongue; THC-infused nasal sprays; and transdermal patches that deliver THC or CBD similar to how a nicotine patch works. Cannabis-infused eye drops have also been discussed.
Newer products include suppositories for the rectum and capsules for the vagina, called transmucosal delivery products because they take advantage of the surface blood supply in these areas of the body.
But what is the future of cannabis delivery? At ebbu, we believe this meaningful plant’s future is limitless, especially when consumers can consistently rely on safe, reliable, repeatable experiences that give them the confidence to try something new.
And when a cannabis consumer buys a product with our stringent “powered by ebbu” seal, they know they can count on that product, be it a bottle of nonalcoholic marijuana beer or a cannabis-infused water, to help them achieve an expected sensation or feeling.
By ebbu Staff
Cannabis has long been used as medicine—going back at least 6,000 years around the world.
Researchers report that records of cannabis use date to 2,700 years ago in Ancient China, where it is believed to have been used as an anesthetic. It played a role in Ayurvedic medicine in India, and its use was also documented in Egyptian papyri.
In Europe, Englishman Robert Burton’s 1621 book The Anatomy of Melancholy offered cannabis to treat depression. Other references pop up in the 1700s, and from 1840 to 1900, when more than 100 papers were published in Western medical journals pointing to the benefits of medical marijuana.
In the 20th century, interest in cannabis for medical purposes had a resurgence thanks to the work of Bulgarian-born Israeli biochemist Dr. Raphael Mechoulam. There’s a reason Dr. Mechoulam is called “The Father of Cannabis Research.” Over the past 50-plus years, he has co-authored upwards of 300 articles in academic journals, been honored by dozens of scientific organizations for his groundbreaking work and appeared at numerous international conferences to push for further research and legalization.
Mechoulam’s first research material took the form of hashish seized by Israeli police that he convinced them to turn over to him to study. Mechoulam went on to map out the structure of the cannabis compound cannabidiol (CBD) in 1963, followed the next year by tetrahydrocannabinol (THC). In 1992, he described the first cannabinoid receptors in the body’s endocannabinoid system, and in 1998, he helped coin the term “entourage effect,” which describes how natural plant compounds—cannabinoids and terpenes—work together to produce different effects than they would individually.
Most importantly, Mechoulam worked with the Israeli government to create one of the world’s first medical marijuana patient programs in 1992, and Israel has since continued to lead the way on cannabis research.
American physician and author Dr. Ethan Russo, also a big name in cannabinoid research, built on Mechoulam’s body of work with a 2008 paper he co-authored, Cannabis and Cannabis Extracts, and another paper published in 2011, where he found synergies among cannabis compounds in the treatment of pain, inflammation, epilepsy, cancer, depression, anxiety, addiction and bacterial infections.
In Spain, Dr. Manuel Guzman is researching the potential of cannabis to fight cancer tumors. And researchers like Dr. Sue Sisley at the Multidisciplinary Association for Psychedelic Studies (MAPS) and Dr. Marcel Bonn-Miller at the University of Pennsylvania have been doing important work looking at the use of cannabis to help veterans suffering from post-traumatic stress disorder (PTSD).
In January 2017, the National Academies of Sciences, Engineering and Medicine made a splash when it released the longitudinal study The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, reviewing 10,000 cannabis studies published since 1999. The report broke down medical uses for cannabis into categories of those with “conclusive,” “substantial,” “moderate” and “limited” evidence, with conclusive evidence listed for efficacy in treating chronic pain, improving multiple sclerosis spasticity and reducing nausea.
Another big turning point for modern cannabis research was in May 2017, when the most rigorous clinical study to date on a cannabis-derived medication was published in the New England Journal of Medicine, confirming what anecdotal evidence has shown for years: CBD has positive effects for many epilepsy patients.
American research has been hobbled by the refusal of the federal government to remove cannabis from the list of Schedule I drugs, where it was placed in 1970. These drugs are said to have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.”
We remain hopeful that these restrictions will soon be lifted, but in the meantime, our ebbu scientists are proud to continue contributing to the knowledge base of cannabis science.
By ebbu Staff
This might just be the best job title ever: Cannabis product tester.
Even better, it’s a real opportunity from Colorado-based cannabis technology lab ebbu, which has spent the last two years conducting clinical research involving panels of adults trying out new products from the company’s high-science development laboratory.
The process actually starts at the cellular level in ebbu’s cellular pharmacology lab, where human receptor activities are measured as they respond to various cannabinoid and terpene combinations. Based on which combinations the cells have the greatest response to, ebbu’s scientists create a small batch of cannabinoids and terpenes mixed into a formulation they believe will create a particular response in the human brain and / or body, whether it’s a profound sense of calm and relaxation or an uptick in excitement and verve.
But to test their hypotheses, ebbu’s team of scientists needs to get real-time reactions from something bigger than a cell. That’s where you, the human trial participant, come in. While human responses are complex and multifaceted, the scientists gain a better understanding of how the interactions they see on the microscopic level play out in real life via these tests.
While these cannabis studies are far from a multiphase, multiyear, multimillion-dollar, FDA-approved clinical trial, they do provide a rigorous and controlled way of measuring the effects of our proprietary formulations that goes beyond anecdotal evidence, something that can have statistical methodology applied to it.
There are not many public results in scientific literature about the effects of rarer cannabinoids on humans. Being part of these studies gives participants the opportunity to be part of cutting-edge research.
So How Does It Work?
Prospective participants for the ebbu studies are asked to fill out a brief survey about their cannabis experience, along with a non-disclosure agreement (NDA) and consent form.
Once they’ve signed the NDA, they learn about the mechanics of the process and can decide whether they want to continue. Participants must be willing to try the product without knowing precisely what it will do, kind of like trying a new strain of cannabis. The test products comply with state laws and pass compliance testing for safety.
Those who seem like good candidates are put into a permanent pool to be invited to studies for which they fit the demographic.
Invited study participants pick up the trial product at a dispensary in a central location in Denver, then conduct the test in the privacy of their own home and give feedback about their experience.
ebbu’s human pharmacology team tallies up all the feedback and shares the results with the cell lab team. Then the cell lab keeps testing and formulating, and the cycle continues.
Studies are currently run every two to three weeks, and participants may be invited to participate in more than one study. In addition to approximately .25 gram of free product, participants also receive a gift card and the knowledge that they are helping move cannabis research forward.
By ebbu Staff
Cannabis researchers working to take the mystery out of cannabis as medicine are digging deeper into the chemical structure of this complex plant, discovering more about the true source of its seemingly magical medical properties. Along the way, they have uncovered an interesting trick—the human body is designed to interact with cannabis, in the form of compounds in the plant known as cannabinoids.
Cannabis researchers have identified two primary cannabinoid receptors: cannabinoid receptor 1 (CB1), predominantly present in the nervous system, particularly the brain and other organs including the adrenal gland, heart, lung, prostate, uterus and ovaries; and cannabinoid receptor 2 (CB2), predominantly found in the immune system.
When cannabis is ingested, your endocannabinoid system interacts naturally with various cannabinoid compounds. Cannabis researchers have been studying the benefits of these interactions as alternative treatments for a variety of human illnesses and conditions, from reproductive health and multiple sclerosis to mental health disorders such as schizophrenia.
The National Cancer Institute reports that cannabinoids can treat the side effects of cancer therapy, and that cannabis has been shown to kill cancer cells in laboratory tests.
Two primary cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC)—discovered by cannabis researchers in 1963 and 1964 respectively—are familiar to most cannabis consumers. THC is the intoxicating cannabinoid of the cannabis plant, used to increase appetite, decrease pain, reduce inflammation and aid in muscle control problems. CBD, a non-psychoactive cannabinoid, also works to decrease pain and inflammation and has been found to be an effective treatment for epileptic seizures.
But those two cannabinoid compounds represent just the tip of the iceberg. Researchers have so far discovered over 100 different cannabinoid compounds from the cannabis plant that can interact with the body’s endocannabinoid system.
Identified cannabinoids include cannabigerol (CBG), an antibiotic; cannabichromene (CBC), an anti-inflammatory; various subsets of THC, including THCV, an analgesic, and THCA, a non-psychoactive cannabinoid acid found in raw cannabis that can be used to treat epilepsy; cannabinol (CBN), a sedative and anticonvulsant; cannabidiolic acid (CBDA), an antibiotic; and cannabifuran (CBF), an antibiotic.
Many other identified cannabinoids, such as cannabitriol (CBT), cannabioxepane (CBX) and cannabinodivarin (CBDV), have been shown to affect the endocannabinoid receptors, and more clinical studies are underway by cannabis scientists, including ebbu’s own research team.
In fact, the National Institute of Health has spent nearly $500 million on research into cannabinoids and the endocannabinoid system since 2015, with another $143 million projected for this year. Their clinical research is examining all classes of cannabinoids, including the molecules that change their concentration or activity, and how these compounds interact with the body’s endocannabinoid system.
In the meantime, anecdotal reports by medical patients about the beneficial effects of cannabis, along with deeper and broader research by scientists, continue building evidence about the efficacy of cannabinoids working in the human body.
And one day, many years from now, we may know all the secrets of this amazing plant, including the ways in which the dozens of other cannabinoids interact with the endocannabinoid system, both individually and in combination with each other, and how those interactions might benefit the humans the cannabis plant seems to naturally want to help.
By Jon Cooper, CEO
In a market brimming with a dizzying array of CBD and THC infused products, how can consumers know what’s safe, what’s reliable and what claims are legitimate?
We created the “Powered by ebbu” label as a way to answer these important consumer questions, to become the household symbol for safety and seal of approval for consistent cannabis experiences—and an overall symbol of trust for the industry. If a product is made with a rigorously tested cannabis formulation that is “Powered by ebbu,” consumers can rely on the real science behind it, delivered in specific doses for a dependable and highly efficacious medical result or adult-use experience.
Consistency is essential for trust and safety regardless of whether you are a pharmaceutical company or a consumer brand. Powered by years of top-level research by scientists experienced in academia and pharmaceuticals, we can say with confidence that the best way to create truly reliable cannabis products is through formulations of purified cannabinoids and terpenes.
When you see “Powered by ebbu,” you might think of a similarly labeled promise often seen on computers: “Intel Inside®.” And the comparison to Intel is not random—as ebbu is a technology platform built on years of laboratory research, designed to support a range of companies in the cannabis space, both medical and recreational. And we’re confident that consumers will come to understand that our “Powered by ebbu” label means that the product you are about to consume will generate consistent, repeatable, known sensations.
We are engaging in strategic business partnerships like our recently-announced collaboration with Keith Villa, the creator of Blue Moon®, to enable the next generation of sophisticated cannabis companies to become recognized as trustworthy brands by consumers. By empowering our partners with formulations that contain a known and precise combination of cannabinoids and terpenes, they can provide a safe, predictable experience for consumers, every time.
To truly deliver on that promise, we will continue our world-class research into cellular and human pharmacology, developing the most effective formulations to achieve specific results, moods and sensations. We’re years ahead of most cannabis research in the United States, but there’s so much to be discovered.
While our partners’ products are “Powered by ebbu,” we are powered by the vision of tapping the full potential of the cannabis plant for the benefit of all.
By ebbu staff
Dr. Brian Reid, ebbu’s Chief Science Officer, is one of the leading minds in the cannabis industry. Dr. Reid oversees all of the research and development that takes place at ebbu, including chemistry, chromatography, cellular pharmacology, human pharmacology and genetics.
His team’s studies of cannabis plant compounds have led to breakthroughs in delivery methods and enlightenment in how specific cannabinoids and terpenes affect mood. For Dr. Reid, the most rewarding part of research into cannabis compounds is making discoveries that have never been reported. He says it feels like “solving a piece of the cannabis puzzle.”
Dr. Reid came to the professional cannabis space by way of the biopharmaceutical industry, where he spent several years as a biochemist and researcher for Gilead Sciences (formerly Myogen) and Incyte. His work focused mainly in drug discovery, finding and discovering new compounds that could potentially go on to become pharmaceutical drugs. The work involved a combination of cellular biology, pharmacology and biochemistry.
Dr. Brian Reid
In 2010 while working at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Dr. Reid founded the High Throughput and High Content Screening Core Facility, which specializes in chemical biology studies. He served as the facility’s director until 2015, as well as teaching research.
In early 2015, ebbu’s CEO, Jon Cooper, approached Dr. Reid’s research department with the idea of conducting studies on ways to combine various cannabinoids and other natural compounds, such as terpenes, to create distinct, consistent, predictable mood effects.
Dr. Reid says, “I had always been interested in psychopharmacology around cannabis, so I worked with Coop [Jon Cooper] to create a proposal for researching potential formulations and studying their effects.” But the university’s lawyers were concerned such research would jeopardize the school’s federal funding and didn’t allow the plan to go forward.
However, Dr. Reid was intrigued enough by the concept that he called Jon and proposed bringing the research in-house to ebbu. The rest, as they say, is history.
Over the past three years, research overseen by Dr. Reid in cellular pharmacology, human pharmacology and genetics has led to breakthroughs in the cannabinoid delivery methodologies, fulfilling the concept he and Cooper originally discussed that centered on discovering which formulations of purified cannabinoids and terpenes lead to consistent, reliable mood effects.
Dr. Reid embraces ebbu’s mission of unlocking the potential of cannabis and cannabinoids to improve people’s quality of life. “What we learned through two years of research on mood effects translates directly to getting at medical effects,” he says.
He and his team are now working to create medical formulations that can be put in any mode of delivery. Formulations that help ease anxiety and pain are the first two areas of focus for ebbu’s lab team.
A dedicated researcher who values sharing findings with the scientific community, Dr. Reid is currently submitting recent ebbu-derived discoveries to peer-reviewed journals. He has previously collaborated on dozens of cellular and biochemistry research papers published in Nature, Journal of Medical Chemistry, Molecular Cell, Biochemistry, Journal of Molecular and Cellular Cardiology, Current Chemical Genomics and Translational Medicine, Antimicrobial Agents and Chemotherapy, Procedures of the National Academy of Science, Expert Opinion on Drug Discovery, Journal of Biomolecular Screening, and The Journal of Biological Chemistry.
He has also been a featured speaker at several top-level medical conferences, including the ACS National Meeting in New Orleans (in the Cannabis Chemistry subgroup); the World Pharma Congress: Epigenetics Screening; the Revolutionaries for Global Health Summit; and the International Meeting on AAA Proteins.
Dr. Reid never strayed from his chosen career path in science. He earned a bachelor’s degree in chemistry from the University of Colorado and a doctorate in biochemistry from the University of Oregon Institute of Molecular Biology. His doctoral dissertation was titled Substrate Specificity of the Molecular Chaperone GroEL/ES: Studies with the Model Proteins Rhodanese and Green Fluorescent Protein. He was a Howard Hughes Postdoctoral Fellow at Yale University School of Medicine, where he focused on mechanistic biochemistry, specifically protein folding and unfolding in vivo.
During his time with the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, he collaborated with specialized programs on the campus and at other institutions, including the School of Medicine, the School of Pharmacy, National Jewish Health and Colorado State University. Most of his work focused on cardiovascular health and cancer.
During his time at the university, he was awarded grants of up to $1 million from the National Institutes of Health, the Colorado Office of Economic Development and International Trade, Colorado’s Bioscience Discovery Evaluation Grant Program, the National Center for Advancing Translational Sciences, The National Institute of Neurological Disorders and Stroke, the Butcher Foundation and Golfers Against Cancer.
By Jon Cooper, CEO
We’ve been approached by lots of folks over the last month asking us, “Why the heck did you give up your license to work with marijuana and THC?” On the surface, we understand that it seems completely unnatural to so happily give up something that we fought so hard to get and maintain over the last few years.
But please read on to understand our reasoning, because we couldn’t be more jazzed about where we’re headed next.
At the end of 2014, the first year adult-use cannabis sales were legal in Colorado, we went through all the required bureaucratic steps to procure a license to produce THC cannabis products.
Over the last three years, we proudly created products that were pure, potent, high-quality and predictable. Our GENESIS product was designed to maximize activation at a particular cannabinoid receptor site in the nervous system (the CB1 receptor site), resulting in a potent, uplifting, functional, repeatable experience. Our Aqua Drops were pre-measured, micro-dosed and dissolvable in practically any liquid. They were fast-acting and sessionable, so that users could take control of their experience. Our WELL products were carefully designed purified cannabis extracts in specific ratios of THC and CBD for consumers seeking the holistic benefits of cannabis.
But after producing our own successful line of products for three years, it became clear that everything we were trying to create in our products was actually a baseline for what mainstream consumers needed in all cannabinoid-based products. Consumers want and deserve safe, consistent, efficacious products that will give them control over dose and titration.
So using our history in the market, we decided to think bigger and better. We wanted to take the wealth of knowledge we had gained to help bring a larger variety of products to market by collaborating with other companies and licensing our one-of-a-kind, industry-leading cannabinoid formulations.
By shifting our focus, we now have the capability to support dozens of other businesses, finding synergy between our technology and their ideas and products. We know there’s a great opportunity to use our scientific research capabilities and technology platform to power other people’s medicines and recreational creations with singular solutions that bring our values—consistency, predictability, repeatability—to a larger group of consumers.
To truly take advantage of our technology platform, we needed to shift to a global perspective. By giving up our THC license and focusing on hemp-derived cannabinoid formulations, we have the opportunity to create products that are not constrained to specific state markets. For example, while our Aqua Drops were previously only available inside state-regulated dispensaries in Colorado, our forthcoming collaboration with Blue Moon founder Keith Villa—a delicious, sessionable, non-alcoholic beer with THC (and other cannabinoids) known as CERIA—will be available wherever Ceria chooses to license and distribute its products.
And our recently announced partnership with Hardy Boy Farms will give ebbu’s botanists the opportunity to test how particular strains perform in the greenhouse environment, continuing ebbu’s patented work in plant genetics to maximize cannabinoid output by boosting in-plant cannabinoid production and cultivating rare-cannabinoid-specific plants. And unlike THC, these non-psychoactive cannabinoids can cross state lines and power products sold outside of the state-regulated cannabis markets—think convenience stores and health food grocers—expanding our formulations’ reach considerably.
We look forward to sharing the results of our research and clinical trials with cannabinoids beyond THC and CBD, as well as the functionality of terpenes.
As we made our way through the early days of regulated cannabis, we immersed ourselves in understanding the complex regulatory processes and requirements. And as we did with our THC license, we are committed to following appropriate regulations around non-THC cannabinoids, making sure that our technology platform can be put to responsible use throughout the U.S. and around the globe.
By ebbu staff
When ebbu founder Jon Cooper first looked at the cannabis industry, one of his early qualms was that he didn’t trust cannabis products in the same way he understood alcohol products.
“When you drink a beer,” he was known for saying, “you have control over the experience—and you can decide how much to drink.” But in 2014 Cooper was rightfully wary of things like cannabis edibles, because he wasn’t sure what effect they would have on him. He decided if he was going to enter the industry, he wanted to create something that would make sense for mainstream consumers like him, something that would help an Average Joe or Jane find that repeatable, predictable experience with a cannabis product.
For more than four years, ebbu has been conducting research and bringing products forward that meet that vision. And now, ebbu is bringing that research into collaborations with other companies.
At the end of March, ebbu told the world that it is partnering with Keith Villa, Ph.D. and the creator (and former head brewmaster) of Blue Moon Brewing Company, to power his just-launched CERIA™ Beverages.
The business, beverage and cannabis worlds all saw the momentous nature of the partnership, with stories quickly appearing in Forbes, USA TODAY, Chicago Sun Times, The Cannabist, NowThis News, High Times, Thrillist, Paste and Cannabis Business Times, among many others.
But why is this collab such a big deal? CERIA is looking to be the first beverage company to introduce a line of non-alcoholic craft beverages containing THC and other cannabinoids and terpenes. By working with ebbu, CERIA will be able to ensure that their products are designed to deliver a fast-acting, consistent, trusted psychoactive experience for consumers.
How fast-acting? Unlike current edibles that can take up to 90 minutes to take effect, these drinks will produce sensations in about the same amount of time as an alcoholic beverage, just as Jon dreamed of years ago.
Keith believes Americans are ready to enjoy a new way of socially consuming cannabis products, by drinking rather than by smoking. Like us, he sees the opportunity and the demand for such products. CERIA is working closely with ebbu to use our patented, lab-tested cannabis formulations, which can be consistently dosed and delivered in a true liquid-soluble format.
These cannabis formulations will be processed and infused into the CERIA concoctions, then sold chilled in licensed dispensaries to consumers 21 and older, first in Colorado, then in other states where the use of recreational marijuana is legal.
(Keith and Jodi Villa)
CERIA will be brewed just like an alcoholic craft beer to maintain its beer taste and aroma, but will then be de-alcoholized prior to the infusion of cannabis. This process means the final product will be have less calories than traditional beer. The drink will come in at least three strengths—light, regular and full-bodied—and offer a choice of sensations, such as chill, bliss and energy.
This partnership furthers our goal of partnering with category-leading companies to mainstream adult-use cannabis by creating consistent, predictable sensations.
We know Keith is the right person to make this groundbreaking mainstream product happen because when he created Blue Moon in 1995, he basically introduced craft beer to the average American beer drinker. It has since of course grown to become the largest craft beer in the country. And Keith also understands the science: He is one of the few people in the world to receive a doctorate in brewing science, writing his dissertation on complex biochemical reactions in beer. In fact, the name CERIA comes from the university campus in Brussles, Belgium where he studied.
We have always loved what Keith stands for, and we are honored and thrilled to partner with him, his wife Jodi and the CERIA team to bring this pioneering product to cannabis consumers. And we seriously can’t wait to get our first sip of CERIA—and to see that “Powered by ebbu” logo on its label.